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Diabetic retinopathy (DR) is an important cause of vision loss around the world, being the leading cause in the population between
20 and 60 years old. Among patients with DR, diabetic macular edema (DME) is the most frequent cause of vision impairment and
represents a significant public health issue. Macular photocoagulation has been the standard treatment for this condition reducing
the risk of moderate visual loss by approximately 50%. The role of vascular endothelial growth factor (VEGF) in DR and DME
pathogenesis has been demonstrated in recent studies. This review addresses and summarizes data from the clinical trials that
investigated anti-VEGF for the management of DME and evaluates their impact on clinical practice. The literature searches were
conducted between August and October 2013 in PubMed and Cochrane Library with no date restrictions and went through the
most relevant studies on pegaptanib, ranibizumab, bevacizumab, and aflibercept for themanagement ofDME.The efficacy and safety
of intravitreal anti-VEGF as therapy for DME have recently been proved by various clinical trials providing significantly positive
visual and anatomical results. Regarding clinical practice, those outcomes have placed intravitreal injection of anti-VEGF as an
option that must be considered for the treatment of DME.
1. Introduction
Obesity is a major risk factor for type 2 diabetes and has
increased in prevalence in the last decades [1, 2]. Diabetic
retinopathy (DR) is a leading cause of vision loss in working-
age patients around the world. One percent of all cases of
blindness worldwide can be attributed to DR [3, 4]. Diabetic
macular edema (DME) is primarily responsible for vision
impairment in diabetic patients [5–7] (Figure 1). A large
epidemiological study indicated that 26% of patients with
diabetic retinopathy presented with DME [8]. According to
another study, the prevalence of macular edema in patients
with recently diagnosed diabetes is 0 to 3%, increasing
to 29% in diabetic patients with over 20 years of disease
[9]. Therefore, ophthalmic complications of the diabetes,
especially DME, represent a significant public health issue
(Figure 2).
Both proliferative and nonproliferative DR may show
DME, which is classified as either focal, if edema is caused
by a focal leakage from microaneurysms, or diffuse, if
generalized leakage from retinal capillaries with abnormal
permeability is observed throughout the posterior pole [10–
12]. Besides the abnormal permeability, edema may also
occur due to occlusion of the capillary bed that leads to
dilation of the patent capillaries and leakage [13].
Controlling DME risk factors such as systemic hyperten-
sion, hyperlipidemia, and poor blood glucose control may
decrease the development of edema and lower progression of
DR [14]. Other risk factors are adult-onset diabetes mellitus,
cardiovascular disease, impaired renal function, advanced
DR, increased number of retinal microaneurysms, and vit-
reomacular traction [13, 15].
The Early Treatment Diabetic Retinopathy Study
(ETDRS) showed the benefit of focal/grid laser for the
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Figure 1: Diabetic retinopathy showing intraretinal hemorrhages,
hard exudates, andmicroaneurysms in the posterior pole associated
with diabetic macular edema.
management of DME, reducing the risk of moderate visual
loss by approximately 50%, and since then, macular photoco-
agulation (MPC) has been the gold standard treatment
[16]. Recently, data from the Diabetic Retinopathy Clinical
Research Network (DRCR.net) studies demonstrated best-
corrected visual acuity (BCVA) improvement of more than
5 letters of vision in 51, 47, and 62% of eyes treated with
monthly 0.5mg of intravitreal ranibizumab after 1, 2, and 3
years of follow-up, respectively [7, 17–19].
Vascular endothelial growth factor (VEGF) is an impor-
tant mediator of blood-retinal barrier breakdown, which
leads to fluid leakage and the development of macular edema
(Figure 3) [20]. Observing that VEGF intraocular levels are
increased in DME, it was hypothesized that alternative or
adjunct therapies using VEGF inhibitors (anti-VEGF) could
be beneficial in reversing vision loss from macular edema
[21].
The aim of this reviewwas to address and compare, where
possible, data from the clinical trials that assessed anti-VEGF
for the management of DME and to evaluate their impact on
clinical practice.
2. Methods
The literature searches were conducted between August and
October 2013 in PubMed and Cochrane Library with no date
restrictions. Relevant unpublished data regarding the topic
“anti-VEGF for the management of diabetic macular edema”
presented at official retina conferences during this period
were also considered in this review. The search strategy used
the following words: diabetic retinopathy, diabetic macular
edema, vascular endothelial growth factor, anti-VEGF, pegap-
tanib,Macugen, bevacizumab,Avastin, ranibizumab,Lucentis,
aflibercept, VEGF Trap Eye, and Eylea.
3. Results and Discussion
On the basis of evidence that VEGF expression and signaling
are deregulated in diabetic retinopathy, anti-VEGF com-
pounds have been studied as a pharmacological alternative
treatment for DME. Considering agents originally used to
treat neovascular age-related macular disease (AMD), recent
trials have addressed the efficacy and safety of different types
of anti-VEGF in the treatment of DME, including pegap-
tanib (Macugen, OSI/Eyetech, USA), ranibizumab (Lucentis,
Genentech, Inc., USA), bevacizumab (Avastin, Genentech,
Inc., USA), and aflibercept (EYLEA, Regeneron Pharmaceu-
ticals, Inc., USA).
Pegaptanib sodium is a selective VEGF antagonist that
binds with the 165 isoform of VEGF and was approved by the
US Food and Drug Administration (FDA) for the treatment
of neovascular AMD [22]. Ranibizumab is a recombinant
humanized immunoglobulin G1 kappa antibody fragment
that binds with and inhibits the biologic activity of all
isoforms of human VEGF-A. It was approved by the FDA
for the treatment of neovascular AMD, macular edema
associated with retinal vein occlusion, and since 2012, it is
approved for the treatment of DME [23]. Bevacizumab is a
full-size, humanized, recombinant monoclonal IgG antibody
that inactivates all VEGF-A isoforms and is approved for
systemic use in the treatment of certain metastatic cancers,
but its use for ocular diseases is off-label. Aflibercept, or
VEGF Trap-Eye, is a new, fully human, 115 kDa recombinant
fusion protein that binds with and inhibits all isoforms of 4
VEGF-A and B as well as binds placental growth factors 1 and
2. It has the advantages of a longer half-life in the eye and a
higher binding affinity for VEGF-A [24]. VEGF Trap-Eye was
approved for the treatment of AMD in 2011 (Table 1) [25].
3.1. Pegaptanib. A phase II randomized double-masked mul-
ticenter controlled trial investigated different doses of intrav-
itreal pegaptanib (0.3, 1, and 3mg) and sham injections in
patients with diabetic macular edema. Data published in
2005 showed that 172 individuals with DME involving the
center of the macula were included with BCVA at baseline
between 20/50 and 20/320. Injections were given at study
entry, week 6, and week 12. Additional injections and/or laser
therapy could be performed as needed, after week 12 until
the end of week 36. Subjects receiving pegaptanib had better
BCVA outcomes compared to sham at week 36, with a larger
proportion of those receiving 0.3mg of the drug having a
visual acuity gain of 2 lines or more (34 versus 10% 𝑃 =
0.003).The same positive results in favor of 0.3mg pegaptanib
were observed with regard to reduction of central retinal
thickness. Subjects assigned to pegaptanib were less likely to
need additional laser therapy [26].
In 2011, a phase-2/3, multicenter, randomized, double-
blinded trial conducted in the United States included 260
subjects with DME involving the center of the macula and
BCVA at baseline between 20/50 and 20/200. They received
0.3mg of either intravitreal pegaptanib or sham injection
every 6 weeks and were followed for 102 weeks. At week
18, macular grid/focal laser was performed as needed, based
on ETDRS criteria. The primary efficacy endpoint was the
proportion gain of 10 letters or more of visual acuity (VA)
from baseline to year 1. No safety issues were identified
throughout the study. Again pegaptanibwas superior to sham
injection regarding visual acuity gain at the end of the first
year (37 versus 20%; 𝑃 = 0.0047). The group treated with
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Figure 2: (a) Fundus photograph of the right eye of a patient with diabetic retinopathy with hard exudates and focal edema temporal superior
to the macula. (b) Optical coherence tomography of the patient showing intraretinal edema and hard exudates.
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Figure 3: VEGF and pathophysiology of diabetic macular edema.
pegaptanib gained 6.1 letters in mean BCVA at week 102,
while the sham injection group gained 1.3 letters (𝑃 < 0.01).
Significantly fewer macular laser indications were observed
in the pegaptanib group compared to sham injection [27].
3.2. Ranibizumab. A small pilot study, in 2006, provided
early data proving that intravitreal ranibizumab was effective
and improved vision acuity in patients with DME. Ten
diabetic patients with chronic macular edema were included
and received intravitreal ranibizumab (IVR) at study entry
and at months 1, 2, 4, and 6. At month 7, the study showed an
improvement in mean visual acuity and reduction in mean
foveal thickness, demonstrating the importance of VEGF in
the pathophysiology of DME [28].
A multicenter, phase II trial, READ-2, was conducted
randomizing 126 subjects with DME evenly into 3 groups:
group 1 received 0.5mg of ranibizumab at baseline and
months 1, 3, and 5; group 2 received focal/grid laser at baseline
and atmonth 3 if needed; and group 3 received a combination
of focal/grid laser and 0.5mg ranibizumab at baseline and at
month 3. The primary outcome was mean change in BCVA
at 6 months. Group 1 (+7.24 letters) was superior to group
2 (−0.43 letters, 𝑃 = 0.01) regarding ETDRS BCVA, while
improvement in group 3 (+3.80 letters) was not significant
compared to the other two groups. A visual gain of 3 lines
or more was observed in 22% in group 1, 0% in group 2, and
8% in group 3 (𝑃 = 0.002) [29].
Table 1: Anti-VEGF agents.
Anti-VEGF
agents
Mechanism of
action
Molecular
weight FDA approval
Pegaptanib
sodium
(Macugen)
Selective VEGF
antagonist (165
isoform).
50 kDa AMD (2004)
Ranibizumab
(Lucentis)
Recombinant
humanized IgG1
kappa antibody
fragment. Inhibits
all isoforms of
human VEGF-A.
48 kDa
AMD (2006)
RVO edema (2010)
DME (2012)
Bevacizumab
(Avastin)
Full-size,
humanized,
recombinant
monoclonal IgG
antibody. Inhibits
all isoforms of
human VEGF-A.
149 kDa Off-label use inophthalmology
Aflibercept
(Eylea)
Fully human
recombinant
fusion protein.
Inhibits all
isoforms of human
VEGF-A and B as
well as binds
placental growth
factors 1 and 2.
115 kDa AMD (2011)RVO edema (2012)
RVO: retinal vein occlusion.
Another phase II clinical trial, RESOLVE, randomized
151 patients with DME to receive either 0.3 or 0.5mg of
ranibizumab asmonotherapy versus sham injection,monthly
for 3 months. After one month, patients were allowed to
have their doses doubled to 0.6mg or 1mg (or double sham)
if indicated by specific study criteria. Both groups were
eligible for rescue laser on the basis of foveal thickness and
visual acuity. Patients in the sham group had their doses
doubledmore often (91.8 versus 68.6%), as well as rescue laser
being more often performed in the sham group (34.7 versus
4.9%). The ranibizumab group had BCVA improvement
averaging +10.3 letters at 1 year, while the sham group
had +1.4 letters (𝑃 < 0.001); the same superiority was
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observed in central retinal thickness improvement, −194.2
versus −48.4𝜇m in the ranibizumab and sham groups,
respectively (𝑃 < 0.001). Visual gain of 10 letters or more
was observed in 60.8% of the ranibizumab-treated patients,
compared with 18.4% of the sham-treated patients (𝑃 <
0.001) [30].
The RESTORE phase III clinical trial conducted in
Europe randomized 345 subjects into 3 different groups: (A)
receiving 0.5mg of ranibizumab and sham laser, (B) receiving
0.5mg of ranibizumab and active laser, and (C) receiving
laser and sham injection. Monthly treatment was given for
3 months followed by “as needed” treatment. In the 12-month
report, visual acuity improvement was 6.1 letters in group A,
5.9 letters in group B, and 0.8 letters with laser alone in group
C.Therewas a statistically significant difference between both
ranibizumab groups and the laser group (𝑃 < 0.0001), but no
differences were seen between the ranibizumab groups.Mean
central retinal thickness also decreased significantly in both
ranibizumab groups compared with laser alone. The mean
number of injections was 7 in the ranibizumab group A and
6.8 in the ranibizumab plus laser group B. No safety issue was
observed in this study [31].
Twomethodologically identical phase III trials, RIDE and
RISE,were intended to support FDAapproval of ranibizumab
for treatment of DME and were sponsored by Genentech
(Genentech Inc., South San Francisco, USA). The parallel,
multicenter, double-masked, sham injection-controlled, ran-
domized studies were conducted in the United States and
South America. RIDE enrolled 377 patients with DME and
RISE enrolled 382. They were evenly assigned to 3 different
groups to receive either 0.3 or 0.5mg of ranibizumab or to
receive sham injections, monthly treatment for 24months. At
3 months, rescue laser was allowed for all patients. After 24
months, the protocol was changed and all patients previously
assigned to sham injections became eligible to receive 0.5mg
ranibizumab injection [32].
At 2 years, RISE and RIDE outcomes showed signifi-
cant superiority of both ranibizumab groups over the sham
injection groups regarding improvement of visual acuity
and reduction of central retinal thickness. The primary
efficacy point was improvement of 15 letters or more, and
considering the sham injection, 0.3mg ranibizumab, and
0.5mg ranibizumab groups, the achievement rate was 18.1,
44.8, and 39.2%of patients in RISE and 12.3, 33.6, and 33.3%of
patients in RIDE. It is worth noting that in the RIDE andRISE
studies there was no direct comparison between ranibizumab
and laser, due to a 3-month delay in laser treatment, even
in the sham groups. Similarly to other ranibizumab trials,
safety findings were acceptable. Endophthalmitis occurred at
a rate of 0.8%. The incidence rates of nonfatal myocardial
infarction, cerebrovascular accident, and death from vascular
or unknown causes were 4.9–5.5% in the sham groups and
2.2–8.8% in the ranibizumab groups. Based on these trials,
FDA approved ranibizumab as the first anti-VEGF for the
treatment of DME.
The same primary endpoint was evaluated at 36 months
and the visual effects were maintained. Improvement of 15
letters or more, in the sham injection, 0.3mg ranibizumab,
and 0.5mg ranibizumab groups was, respectively, 22.0, 41.6,
and 51.2% in RISE patients and 19.2, 36.8, and 40.2% in RIDE
patients [33].
The Diabetic Retinopathy Clinical Research Network
(DRCR.net) conducted a study with a more complicated
design. Although other trials had shown the benefits of anti-
VEGF as a treatment forDME,monthly injections ormonthly
evaluations were not feasible in clinical practice. DRCR.net
protocol I tried to give more flexibility to the treatment
and to differentiate between the effect of ranibizumab and
laser. A total of 854 patients with DME were randomized
into 4 groups: sham injection plus prompt laser; 0.5mg
ranibizumab plus prompt laser, 0.5mg ranibizumab plus
deferred laser (at or after 24 weeks), and 4mg triamcinolone
plus prompt laser. Treatment was given according to the
“4 : 2 : 7 rule”: four monthly injections; additional injections
if required at the next 2 study visits, and 7 subsequent
study visits during which injection could be indicated at the
investigator’s discretion if the study eye was considered to
show “no improvement” [17].
The primary outcome was mean change in BCVA at 1
year and the findings showed that both ranibizumab groups,
with prompt or deferred laser, gained 9 letters, superior to the
triamcinolone plus laser and sham plus laser groups, which
gained 4 and 3 letters, respectively. At 2 years, improvements
in mean change in BCVA were maintained and fewer injec-
tions were performed in the ranibizumab groups throughout
the second year: from 8 in the prompt laser and 9 in the
deferred to 2 and 3, respectively. It is noteworthy that the
number of injections was similar between prompt laser group
and deferred laser group [17].
Data from the third year of protocol I suggest that early
initiation of focal/grid laser treatment not only lacks benefit
but also may be detrimental to visual outcomes, since the
deferred laser group showed 57% of patients gaining 10 letters
or more and 5% losing 10 letters or more, while the prompt
laser group showed 42% gaining 10 or more letters and 10%
losing 10 or more letters [34].
An exploratory analysis of protocol I was performed to
evaluate the effect of intravitreal ranibizumab and triamci-
nolone on worsening diabetic retinopathy. Despite acknowl-
edging the limitations of exploratory analysis, the results
indicated that ranibizumab, as well as triamcinolone, appears
to reduce the risk of worsening diabetic retinopathy [35].
3.3. Bevacizumab. Intravitreal bevacizumab (IVB) has been
widely used off-label for the treatment of AMD, espe-
cially because of its significantly lower cost compared to
ranibizumab, in addition to positive clinical effects demon-
strated in early studies [36].Thewidespread use of IVB for the
management of DME led to the need of a formal evaluation
of its safety and efficacy [37–39].
DRCR.net conducted a phase II exploratory trial includ-
ing 121 eyes with DME over a 12-week period to assess the
short-term effect of IVB [39].The eyes were randomized into
five groups: (I) focal laser, (II) two intravitreal injections of
1.25mg of bevacizumab at 0 and 6weeks, (III) two intravitreal
injections of 2.5mg of bevacizumab at 0 and 6 weeks, (IV)
1.25mg of bevacizumab at week 0 followed by a sham
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injection at week 6, and (V) 1.25mg of bevacizumab at 0 and
6 weeks plus focal laser at 3 weeks. Eyes assigned to groups II
and III had a significant BCVA improvement over the laser-
only group I, and this difference was seen throughout the
12 weeks. These two groups also had a greater improvement
in central subfield thickness (CST) at the 3-week visit. No
differences were seen between groups 1.25mg and 2.5mg
bevacizumab. The single injection group was not superior
to the laser group. Bevacizumab plus laser showed results
comparable to laser-only treatment. This study suggested
that bevacizumab was an effective drug for treating DME
as a primary treatment and also for refractory eyes, since
69% of included eyes were refractory to previous treatment.
However, eyes that received primary treatment had greater
improvement than the refractory ones (𝑃 = 0.04). No safety
concerns were detected in 24 weeks. Similar outcomes show-
ing no difference between 1.25mg and 2.5mg of bevacizumab
have been previously reported in other studies [40, 41].
A randomized clinical trial compared IVB injection alone
or in combination with intravitreal triamcinolone acetonide
(IVT) versus macular laser photocoagulation as a primary
treatment for DME. A total of 150 eyes were randomly
assigned to the following groups: (I) 1.25mg IVB, (II)
IVB/IVT, with 1.25mg IVB and 2mg IVT, and (III) macular
laser. The IVB group showed significant superiority in visual
acuity improvement after six months, but this was not
sustained after 24 months. The mean BCVA was significantly
better in the IVB-only group compared to baseline, after 24
weeks [7, 42].
The study conducted by the Pan-American Collabo-
rative Retina Study Group (PACORES) examined IVB as
the primary treatment for diffuse DME at 11 centers in 8
countries [38].This retrospective,multicenter, interventional,
comparative case series reviewed clinical data of 139 eyes
with diffuse DME treated with at least 1 off-label intravitreal
injection of either 1.25 or 2.5mg of bevacizumab. The dose
received at baseline was the same dose delivered throughout
the study. Follow-up considered BCVA measurement with
ETDRS charts and OCT at baseline and 1, 3, 6, 12, and 24
months after the initial injection. The reinjection criterion
was recurrence of diffuse DME [43].
No significant differences between the 1.25mg and 2.5mg
dose groups were detected. Mean BCVA and central macular
thickness (CMT) improved at 1 month after the first IVB
and such significant outcomes were sustainable all along the
24 months; when the results demonstrated that 72 (51.8%)
eyes improved by 2 or more ETDRS lines, 62 (44.6%) eyes
remained stable, and 5 (3.6%) eyes decreased by 2 or more
ETDRS lines of BCVA. At 24 months, OCT analysis showed
that CMT decreased from 446.4 ± 154.4 to 279.7 ± 80 𝜇m.
Themean number of injections per eye was 5.8 (range of 1–15
injections) at a mean interval of 12.2 ± 10.4 weeks [43].
The bevacizumab or laser therapy (BOLT) study is a
prospective, randomized, blinded, single-center study that
compared IVB to macular laser photocoagulation in patients
with persistentDMEafter at least onemacular laser treatment
[44]. Eighty eyes were randomized into either the beva-
cizumab group, receiving injections every 6 weeks, with a
minimum of 3 and a maximum of 9 injections, or the laser
group, receiving treatment every 4 months, with a minimum
of 1 and a maximum of 4 treatments. Mean BCVA after 1 year
increased in the bevacizumab group and declined in the laser
group. The CMT results were superior in the bevacizumab
group as well. The mean number of interventions was 9
injections and 3 laser treatments during the first year.
The 2-year outcome report from the BOLT study was
published in 2012 and presented similar results to those
obtained in the first year report [45]. The mean BCVA was
20/50 in the group treated with bevacizumab and 20/80 in
the laser group (𝑃 = 0.005), with a mean gain of 8.6 letters
for bevacizumab versus a mean gain of 0.5 letters for the laser
group. Regarding improvement of 15 letters or more, 32% of
the eyes treated with bevacizumab achieved this target versus
4% for the laser-treated eyes (𝑃 = 0.004). On the other hand,
the proportion of subjects that lost fewer than 15 letters in the
laser group was 86% versus 100% for the bevacizumab group
(𝑃 = 0.03). CMT decreased significantly in both groups at
2-year follow-up and the mean number of treatments was 13
injections and 4 macular laser interventions.These outcomes
provided by the BOLT study support the longer term use of
IVB for the treatment of DME.
3.4. Aflibercept. Encouraged by positive results from a phase
I study [46], a phase II, multicenter, randomized clinical trial
was conducted to investigate different dosing regimens of
intravitreal VEGF Trap-Eye for the treatment of DME com-
pared to standardmacular laser [24].TheDAVINCI (DMEA
and VEGF Trap-Eye: Investigation of Clinical Impact) study
enrolled 221 subjects with center-involved DME and BCVA
between 20/40 and 20/320 randomized into 5 groups: 0.5mg
VEGF Trap-Eye every 4 weeks (0.5q4), 2.0mg VEGF Trap
Eye every 4 weeks (2q4), 2.0mg VEGF Trap Eye monthly for
3 months and then every 8 weeks (2q8), 2.0mg VEGF Trap
Eye monthly for 3 months and then as needed (2 PRN), and
macular laser treatment. All VEGF Trap Eye groups received
sham laser and all laser patients received sham injection.The
primary endpoint was mean change in BCVA. The change
from baseline in central retinal thickness and proportion of
patients gaining at least 15 letters at week 24 were among
secondary outcomes [24].
Improvement in mean change of BCVA was observed
ranging from 8.5 to 11.4 letters in groups receiving aflibercept
versus 2.5 letters in the laser group, at week 24. Central
retinal thickness significantly decreased more in the groups
treated with VEGF Trap-Eye compared to the laser group.
No significant differences were seen between the aflibercept
groups, supporting a treatment regimen of every 8 weeks
instead of every 4weeks [24]. At 52weeks, the change inmean
BCVA ranged from 9.7 to 13.1 letters in the aflibercept groups
versus a loss of 1.3 letters in the laser group [47].
Two phase III trials are ongoing and have recently
divulged early outcomes. VIVID-DME (VEGF Trap-Eye in
Vision Impairment due to DME), in Europe, Japan, and
Australia, and VISTA-DME (Study of Intravitreal Adminis-
tration of VEGF Trap-Eye in Patients with Diabetic Macular
Edema), in USA, are randomized, double-masked, active
controlled trials that investigate the efficacy and safety of
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repeated doses of intravitreal VEGFTrap-Eye in subjects with
DME [48]. The trials are both sponsored by Bayer (Bayer
AG, Leverkusen, Germany) and Regeneron Pharmaceuticals
(Regeneron Pharmaceuticals, Inc., Tarrytown,USA) andmay
support the FDA approval for the use of aflibercept in DME
[49, 50].
VIVID-DME enrolled 404 patients andVISTA-DME461,
randomized (1 : 1 : 1) to receive intravitreally either 2.0mg
aflibercept every 4 weeks (2q4) or 2.0mg aflibercept every
8 weeks after 5 initial monthly doses (2q8) or laser photo-
coagulation. Primary endpoint was mean change in BCVA
at week 52. The patients were scheduled for continued
treatment for 3 years [48]. After the first year, the primary
results showed the superiority of aflibercept groups over
the laser treatment group. Mean change in BCVA in the
VIVID-DME study was plus 10.7 letters in the 2q8 group
and plus 10.5 in the 2q4 versus plus 1.2 in the laser group.
The VISTA-DME showed a similar mean change in BCVA
of plus 10.7 letters in the 2q8, plus 12.5 in the 2q4, and
plus 0.2 in the laser group. The mean change in central
retinal thickness, proportion of patients gaining at least 15
letters, and improvement of Diabetic Retinopathy Severity
Score (DRSS), all secondary outcomes, showed a significant
superiority of aflibercept over laser treatment. On average,
the aflibercept 2q8 group performed similarly as the afliber-
cept 2q4 group. No systemic safety signal was detected
in either aflibercept treatment group through week 52
[48].
4. Further Study and Concerns
The efficacy of intravitreal anti-VEGF for the treatment of
DME has recently been proved by various studies. Safety
issues concerning intravitreal injection of anti-VEGF are
well known from AMD studies, although none of those
trials or DME trials had enough power to detect significant
differences between the study groups regarding adverse
events. Serious ocular adverse events are of low frequency
and include endophthalmitis, uveitis, and retinal detachment;
likewise the risk of occurrence does not seem to be greater in
patients with DME than in AMD. Serious systemic adverse
events could be death, myocardial infarction, and stroke.
Most safety studies, however, have failed to identify issues
regarding such systemic events related to intravitreal anti-
VEGF injection [32, 36, 47, 48].
The small number of relevant trials and variation in
their characteristics limit comparisons between different
anti-VEGF drugs. A relevant ongoing study conducted by
the DRCR.net, the protocol T, proposes as its primary
objective to compare the efficacy and safety of intravitreal
aflibercept, bevacizumab, and ranibizumab when used to
treat central-involved DME. To date, 660 subjects with DME
and BCVA between 20/32 and 20/320 were enrolled and will
be randomized to receive either 1.25mg bevacizumab, or
0.3mg ranibizumab, or 2.0mg aflibercept [51]. Considering
that ranibizumab is the only approved anti-VEGF for DME,
the markedly lower cost of bevacizumab, and the potential of
aflibercept to decrease treatment burden and associated cost,
the outcomes from this study should have an extensive impact
on clinical practice regarding the management of DME.
5. Conclusions
Diabetic macular edema is an important cause of vision
impairment and macular photocoagulation has been the
standard treatment for this condition. Recent studies have
presented significantly positive visual and anatomical results
regarding the use of anti-VEGF for the treatment of
DME, both as primary intervention and in refractory
cases. Although the protocols are all consistently different,
undoubtedly anti-VEGF therapy has assumed an important
role in the management of DME, either as a first choice or as
adjuvant to photocoagulation.
This review was conducted to better understand the
impact of the outcomes of recent trials on clinical practice.
Further studies are necessary, especially to investigate long-
term efficacy and safety, to compare drugs, and establish
guidelines. However, confronted with a diagnosis of center-
involved diabetic macular edema, it has become mandatory
to consider treatment with intravitreal anti-VEGF injections.
Conflict of Interests
Theauthors have no conflict of interests regarding the present
study.
Acknowledgments
The authors would like to thank FAPESP (Fundac¸a˜o de
Amparo a` Pesquisa do Estado de Sa˜o Paulo) and CNPq
(Conselho Nacional de Pesquisa). Also, they thank Dr. A.
Leyva who helped them with English editing of the paper.
References
[1] A. E. Pontiroli and L. Galli, “Duration of obesity is a risk factor
for non-insulin-dependent diabetes mellitus, not for arterial
hypertension or for hyperlipidaemia,” Acta Diabetologica, vol.
35, no. 3, pp. 130–136, 1998.
[2] V. S. Malik, W. C. Willett, and F. B. Hu, “Global obesity:
trends, risk factors and policy implications,” Nature Reviews
Endocrinology, vol. 9, no. 1, pp. 13–27, 2013.
[3] B. E. K. Klein, “Overview of epidemiologic studies of diabetic
retinopathy,” Ophthalmic Epidemiology, vol. 14, no. 4, pp. 179–
183, 2007.
[4] D. Pascolini and S. P. Mariotti, “Global estimates of visual
impairment: 2010,”British Journal of Ophthalmology, vol. 96, no.
5, pp. 614–618, 2012.
[5] B. P. Nicholson and A. P. Schachat, “A review of clinical trials
of anti-VEGF agents for diabetic retinopathy,” Graefe’s Archive
for Clinical and Experimental Ophthalmology, vol. 248, no. 7, pp.
915–930, 2010.
[6] R. Klein, B. E. K. Klein, and S. E. Moss, “Visual impairment in
diabetes,” Ophthalmology, vol. 91, no. 1, pp. 1–9, 1984.
[7] M. Soheilian, K. H. Garfami, A. Ramezani, M. Yaseri, and G. A.
Peyman, “Two-year results of a randomized trial of intravitreal
bevacizumab alone or combined with triamcinolone versus
Journal of Immunology Research 7
laser in diabetic macular edema,” Retina, vol. 32, no. 2, pp. 314–
321, 2012.
[8] Early Treatment Diabetic Retinopathy Study Research Group,
“Early photocoagulation for diabetic retinopathy ETDRS report
number 9,” Ophthalmology, vol. 98, no. 5, pp. 766–785, 1991.
[9] R. Klein, B. E. K. Klein, and S. E. Moss, “The Wisconsin epi-
demiologic study of diabetic retinopathy. IV. Diabetic macular
edema,” Ophthalmology, vol. 91, no. 12, pp. 1464–1474, 1984.
[10] G. E. Lang and S. J. Lang, “Klinik und therapie des diabetischen
makulao¨dems,” Klinische Monatsblatter fu¨r Augenheilkunde,
vol. 228, no. 1, pp. R1–R13, 2011.
[11] G. E. Lang, “Diabetic macular edema,” Ophthalmologica, vol.
227, supplement 1, pp. 21–29, 2012.
[12] F. R. Stefanini, J. F. Arevalo, and M. Maia, “Bevacizumab for
the management of diabetic macular edema,” World Journal of
Diabetes, vol. 4, no. 2, pp. 19–26, 2013.
[13] P. G. Tranos, S. S. Wickremasinghe, N. T. Stangos, F. Topouzis,
I. Tsinopoulos, and C. E. Pavesio, “Macular edema,” Survey of
Ophthalmology, vol. 49, no. 5, pp. 470–490, 2004.
[14] H. Shamoon,H.Duffy,N. Fleischer et al., “The effect of intensive
treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes melli-
tus,” The New England Journal of Medicine, vol. 329, no. 14, pp.
977–986, 1993.
[15] J. M. Lopes De Faria, A. E. Jalkh, C. L. Trempe, and J. W.
McMeel, “Diabetic macular edema: risk factors and concomi-
tants,” Acta Ophthalmologica Scandinavica, vol. 77, no. 2, pp.
170–175, 1999.
[16] Early Treatment Diabetic Retinopathy Study Research Group,
“Photocoagulation for diabetic macular edema. Early treatment
diabetic retinopathy study report number 1,” Archives of Oph-
thalmology, vol. 103, no. 12, pp. 1796–1806, 1985.
[17] M. J. Elman, L. P. Aiello, R. W. Beck et al., “Randomized
trial evaluating ranibizumab plus prompt or deferred laser or
triamcinolone plus prompt laser for diabetic macular edema,”
Ophthalmology, vol. 117, no. 6, pp. 1064–1077, 2010.
[18] Diabetic Retinopathy Clinical Research Network, “A random-
ized trial comparing intravitreal triamcinolone acetonide and
focal/grid photocoagulation for diabetic macular edema,”Oph-
thalmology, vol. 115, no. 9, pp. 1447–1459, 2008.
[19] R.W. Beck, A. R. Edwards, L. P. Aiello et al., “Three-year follow-
up of a randomized trial comparing focal/grid photocoagula-
tion and intravitreal triamcinolone for diabeticmacular edema,”
Archives of Ophthalmology, vol. 127, no. 3, pp. 245–251, 2009.
[20] T. Qaum, Q. Xu, A. M. Joussen et al., “VEGF-initiated blood-
retinal barrier breakdown in early diabetes,” Investigative Oph-
thalmology and Visual Science, vol. 42, no. 10, pp. 2408–2413,
2001.
[21] H. Funatsu, H. Yamashita, H. Noma, T. Mimura, T. Yamashita,
and S. Hori, “Increased levels of vascular endothelial growth
factor and interleukin-6 in the aqueous humor of diabetics with
macular edema,” American Journal of Ophthalmology, vol. 133,
no. 1, pp. 70–77, 2002.
[22] Administration USFaD, FDA Approves New Drug Treatment
for Age-Related Macular Degeneration, 2004, http://www.
.fdagov/newsevents/newsroom/pressannouncements/2004/
ucm108385.htm.
[23] Administration USFaD, FDA Approves Lucentis To Treat Dia-
betic Macular Edema, 2012, http://www.fda.gov/newsevents/
newsroom/pressannouncements/ucm315130.htm.
[24] D. V. Do, U. Schmidt-Erfurth, V. H. Gonzalez et al., “The da
VINCI study: Phase 2 primary results of VEGF trap-eye in
patients with diabetic macular edema,”Ophthalmology, vol. 118,
no. 9, pp. 1819–1826, 2011.
[25] Administration USFaD, FDAApproves Eylea for Eye Disorder in
Older People, 2011, http://www.fda.gov/newsevents/newsroom/
pressannouncements/ucm280601.htm.
[26] B. Katz, “A phase II randomized double-masked trial of pegap-
tanib, an anti-vascular endothelial growth factor aptamer, for
diabetic macular edema,” Ophthalmology, vol. 112, no. 10, pp.
1747–1757, 2005.
[27] M. B. Sultan, D. Zhou, J. Loftus, T. Dombi, and K. S. Ice,
“A phase 2/3, multicenter, randomized, double-masked, 2-year
trial of pegaptanib sodium for the treatment of diabeticmacular
edema,” Ophthalmology, vol. 118, no. 6, pp. 1107–1118, 2011.
[28] Q. D. Nguyen, S. Tatlipinar, S. M. Shah et al., “Vascular
endothelial growth factor is a critical stimulus for diabetic
macular edema,” American Journal of Ophthalmology, vol. 142,
no. 6, pp. 961.e4–969.e4, 2006.
[29] Q. D. Nguyen, S. M. Shah, J. S. Heier et al., “Primary end point
(six months) Results of the Ranibizumab for Edema of The
Macula in Diabetes (READ-2) Study,” Ophthalmology, vol. 116,
no. 11, pp. 2175.e1–2181.e1, 2009.
[30] P. Massin, F. Bandello, J. G. Garweg et al., “Safety and efficacy
of ranibizumab in diabetic macular edema (RESOLVE study): a
12-month, randomized, controlled, double-masked, multicen-
ter phase II study,” Diabetes Care, vol. 33, no. 11, pp. 2399–2405,
2010.
[31] P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al., “The
RESTORE study: ranibizumab monotherapy or combined with
laser versus laser monotherapy for diabetic macular edema,”
Ophthalmology, vol. 118, no. 4, pp. 615–625, 2011.
[32] Q. D. Nguyen, D. M. Brown, D. M. Marcus et al., “Ranibizumab
for diabeticmacular edema: results from 2 phase iii randomized
trials: RISE and RIDE,” Ophthalmology, vol. 119, no. 4, pp. 789–
801, 2012.
[33] D. M. Brown, Q. D. Nguyen, D. M. Marcus et al., “Long-term
outcomes of ranibizumab therapy for diabetic macular edema:
the 36-month results from two phase III trials: RISE and RIDE,”
Ophthalmology, vol. 120, no. 10, pp. 2013–2022, 2013.
[34] M. J. Elman, H. Qin, L. P. Aiello et al., “Intravitreal ranibizumab
for diabetic macular edema with prompt versus deferred laser
treatment: three-year randomized trial results,”Ophthalmology,
vol. 119, no. 11, pp. 2312–2318, 2012.
[35] S. B. Bressler, H. Qin, M. Melia et al., “Exploratory analysis
of the effect of intravitreal ranibizumab or triamcinolone on
worsening of diabetic retinopathy in a randomized clinical
trial,” JAMAOphthalmology, vol. 131, no. 8, pp. 1033–1040, 2013.
[36] D. F. Martin, M. G. Maguire, G.-S. Ying, J. E. Grunwald,
S. L. Fine, and G. J. Jaffe, “Ranibizumab and bevacizumab
for neovascular age-related macular degeneration,” The New
England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908,
2011.
[37] T. Yilmaz,M. Cordero-Coma,M. J. Gallagher, and L. A. Teasley,
“Systematic review of intravitreal bevacizumab injection for
treatment of primary diabetic macular oedema,” Acta Ophthal-
mologica, vol. 89, no. 8, pp. 709–717, 2011.
[38] J. F. Arevalo, J. Fromow-Guerra, H. Quiroz-Mercado et al., “Pri-
mary intravitreal bevacizumab (Avastin) for diabetic macular
edema. Results from the Pan-American Collaborative Retina
Study Group at 6-month follow-up,” Ophthalmology, vol. 114,
no. 4, pp. 743–750, 2007.
8 Journal of Immunology Research
[39] I. U. Scott, A. R. Edwards, R. W. Beck et al., “A phase II ran-
domized clinical trial of intravitreal bevacizumab for diabetic
macular edema,” Ophthalmology, vol. 114, no. 10, pp. 1860–1867,
2007.
[40] F. Arevalo, J. G. Sanchez, J. Fromow-Guerra et al., “Comparison
of two doses of primary intravitreal bevacizumab (Avastin)
for diffuse diabetic macular edema: results from the Pan-
American Collaborative Retina Study Group (PACORES) at 12-
month follow-up,”Graefe’s Archive for Clinical and Experimental
Ophthalmology, vol. 247, no. 6, pp. 735–743, 2009.
[41] D. S. C. Lam, T. Y. Y. Lai, V. Y. W. Lee et al., “Efficacy of 1.25mg
versus 2.5mg intravitreal bevacizumab for diabetic macular
edema: Six-month results of a randomized controlled trial,”
Retina, vol. 29, no. 3, pp. 292–299, 2009.
[42] M. Soheilian, A. Ramezani, A. Obudi et al., “Randomized trial
of intravitreal bevacizumab alone or combined with triamci-
nolone versus macular photocoagulation in diabetic macular
edema,” Ophthalmology, vol. 116, no. 6, pp. 1142–1150, 2009.
[43] J. F. Arevalo, J. G. Sanchez, L. Wu et al., “Primary intravitreal
bevacizumab for diffuse diabetic macular edema. The Pan-
American Collaborative Retina Study Group at 24 months,”
Ophthalmology, vol. 116, no. 8, pp. 1488.e1–1497.e1, 2009.
[44] M.Michaelides, A. Kaines, R. D. Hamilton et al., “A prospective
randomized trial of intravitreal bevacizumab or laser therapy
in the management of diabetic macular edema (BOLT Study).
12-month data: report 2,” Ophthalmology, vol. 117, no. 6, pp.
1078.e2–1086.e2, 2010.
[45] R. Rajendram, S. Fraser-Bell, A. Kaines et al., “A 2-year prospec-
tive randomized controlled trial of intravitreal bevacizumab or
laser therapy (BOLT) in the management of diabetic macular
edema: 24-month data: report 3,” Archives of Ophthalmology,
vol. 130, no. 8, pp. 972–979, 2012.
[46] D. V. Do, Q. D. Nguyen, S. M. Shah et al., “An exploratory study
of the safety, tolerability and bioactivity of a single intravitreal
injection of vascular endothelial growth factor Trap-Eye in
patients with diabetic macular oedema,” The British Journal of
Ophthalmology, vol. 93, no. 2, pp. 144–149, 2009.
[47] D. V. Do, Q. D. Nguyen, D. Boyer et al., “One-year outcomes
of the DA VINCI study of VEGF trap-eye in eyes with diabetic
macular edema,” Ophthalmology, vol. 119, no. 8, pp. 1658–1665,
2012.
[48] “Intravitreal aflibercept injection for diabetic macular edema:
primary results,” in Proceedings of the 46th Retina Society
Annual ScientificMeeting, D.M. Brown, Ed., BeverlyHills, Calif,
USA, September 2013.
[49] Clinicaltrials.gov, Study of Intravitreal Administration of
VEGF Trap-Eye (BAY86-5321) in Patients With Diabetic
Macular Edema (VISTA DME), ClinicalTrials.gov Identifier:
NCT01363440, 2013, http://clinicaltrials.gov/show/
NCT01363440.
[50] Clinicaltrials.gov, VEGF Trap-Eye in Vision Impairment
Due to DME (VIVID-DME), ClinicalTrials.gov Identifier:
NCT01331681, 2013, http://clinicaltrials.gov/show/
NCT01331681.
[51] Clinicaltrials.gov, Comparative Effectiveness Study of Intrav-
itreal Aflibercept, Bevacizumab, and Ranibizumab For DME
(Protocol T). Diabetic Retinopathy Clinical Research Network,
Identifier: NCT01627249, 2013, http://clinicaltrials.gov/show/
NCT01627249.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
